Gleason Score News and Research

RSS

Long-term oncologic outcomes: A 40 year radical prostatectomy single institution series

Single institution long-term outcomes for radical prostatectomy are scarce in the literature. In the August 2006 issue of the Journal of Urology, Dr. Porter from the Virginia Mason Medical Center, Seattle, WA reports on 25-year cancer outcomes for radical prostatectomy (RP).

6 Sep 2006

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Intermittent androgen deprivation (IAD) is commonly used in the treatment of CaP, which theoretically may delay the development of hormone resistance.

17 Aug 2006

Pomegranate juice may decrease PSA progression in patients with cancer recurrence after treatment

Because of their high content of antioxidants, pomegranate juice is frequently recommended for cancer prevention and overall wellness. While small studies have suggested a role against prostate carcinogenesis, no organized trials have been published until now.

17 Aug 2006

When a patient is diagnosed with prostate cancer, what determines whether he will receive early androgen ablation?

While the benefits of androgen ablation therapy have been well documented in patients with locally advanced and metastatic prostate cancer, there is a paucity of evidence its role in patients with low-grade, low-stage disease.

16 Aug 2006

New diagnostic tool for prostate cancer

According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.

19 Jul 2006

A new diagnostic tool for prostate cancer

According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.

12 Jul 2006

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Intermittent androgen deprivation (IAD) is commonly used in the treatment of CaP, which theoretically may delay the development of hormone resistance.

29 Jun 2006

Shift in prostate cancer Gleason grades from 1989 to 2001

Since the clinical introduction of PSA testing, there is reason to hypothesize that prostate cancer (CaP) Gleason grades may have shifted due to a variety of factors.

26 Jun 2006

Monitoring anemia provides clues to prostate cancer treatment response

Researchers from the Oregon Health & Science University Cancer Institute and Southwest Oncology Group have identified a new method of determining how men with advanced prostate cancer will respond to treatment.

1 Jun 2006

Usage and outcomes of primary androgen deprivation therapy for localized prostate cancer

In the online March 2006 version of Cancer, Dr. Kawakami and associates report from the CaPSURE database that primary androgen deprivation therapy (PADT) is used in 14% of prostate cancer (CaP) patients with reasonable outcomes at approximately 5 years follow-up.

11 Apr 2006

Delayed prostate cancer intervention in low risk patients may not decrease ultimate chance for cure

A contemporary discussion exists whether patients with low-risk prostate cancer (CaP) are being overtreated with local treatment modalities. This is due to a combination of the older population affected and the slow doubling time of CaP.

23 Mar 2006

Androgen deprivation therapy does not prevent prostate cancer from spreading

Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of testosterone actually keeps cancer from spreading beyond the prostate.

27 Feb 2006

Benefit of combining radiation and hormone therapy in the treatment of prostate cancer

Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer

1 Nov 2005

Researchers identify biomarker that indicates a more agressive form of prostate cancer

Staging factors for prostate cancer such as PSA and the Gleason score are extremely useful in predicting prostate cancer outcome," explained Pollack. "However, new biomarkers hold promise in strengthening our ability to predict response to treatment. By identifying the more virulent forms of prostate cancer, we may be able to tailor treatment or develop therapies to target the abnormalities identified."

17 Oct 2005

Aggressive management of diabetes with diet, exercise, and medications may improve the survival of cancer patients

Researchers at Fox Chase Cancer Center found no effects of type II diabetes on aggressiveness of prostate cancer but found that long-term survival is worse. The findings were presented at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Denver, Colo.

16 Oct 2005

Rapid weight gain between the ages of 25 and 40 doubles likelihood of prostate cancer recurrence

Men who gain weight rapidly between the ages of 25 and 40 are twice as likely to have recurrence of prostate cancer after surgery as men without rapid rates of weight gain, researchers from University of Texas M. D. Anderson Cancer Center reported in the October 1 issue of "Clinical Cancer Research."

4 Oct 2005

Clinical factors can help predict the risk of prostate cancer death for patients following a radical prostatectomy

Clinical factors including the time to biochemical recurrence following surgery can help predict the risk of prostate cancer death for patients following a radical prostatectomy, according to a study in the July 27 issue of JAMA: The Journal of the American Medical Association.

27 Jul 2005

Rate of increase in PSA value predicts risk of death following radiation therapy

Men who have a higher rate of increase in their PSA value in the year prior to their prostate cancer diagnosis have a significantly higher risk of death following radiation therapy, according to a study in the July 27 issue of JAMA: The Journal of the American Medical Association.

26 Jul 2005

Tool helps determine who is at high risk of death after prostate cancer recurrence following surgery

Researchers at Johns Hopkins and The Brady Urological Institute have identified three risk factors and developed a simple reference tool that doctors can use to determine who is at high risk of death after prostate cancer recurrence following surgery.

26 Jul 2005

Identifying high-risk prostate cancer means more prudent treatment decisions

While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening.

16 May 2005

Gleason Score News and Research

Long-term oncologic outcomes: A 40 year radical prostatectomy single institution series

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Pomegranate juice may decrease PSA progression in patients with cancer recurrence after treatment

When a patient is diagnosed with prostate cancer, what determines whether he will receive early androgen ablation?

New diagnostic tool for prostate cancer

A new diagnostic tool for prostate cancer

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Shift in prostate cancer Gleason grades from 1989 to 2001

Monitoring anemia provides clues to prostate cancer treatment response

Usage and outcomes of primary androgen deprivation therapy for localized prostate cancer

Delayed prostate cancer intervention in low risk patients may not decrease ultimate chance for cure

Androgen deprivation therapy does not prevent prostate cancer from spreading

Benefit of combining radiation and hormone therapy in the treatment of prostate cancer

Researchers identify biomarker that indicates a more agressive form of prostate cancer

Aggressive management of diabetes with diet, exercise, and medications may improve the survival of cancer patients

Rapid weight gain between the ages of 25 and 40 doubles likelihood of prostate cancer recurrence

Clinical factors can help predict the risk of prostate cancer death for patients following a radical prostatectomy

Rate of increase in PSA value predicts risk of death following radiation therapy

Tool helps determine who is at high risk of death after prostate cancer recurrence following surgery

Identifying high-risk prostate cancer means more prudent treatment decisions

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News